{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:39:02Z","timestamp":1770820742800,"version":"3.50.1"},"reference-count":66,"publisher":"Informa UK Limited","issue":"15","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.2217\/imt-2023-0012","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T08:34:33Z","timestamp":1689755673000},"page":"1199-1208","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3158-8014","authenticated-orcid":false,"given":"Jurij","family":"Hanzel","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, University of Ljubljana, Ljubljana, 1000, Slovenia"},{"name":"Alimentiv Inc, London, Ontario, N6A 5B6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-9948","authenticated-orcid":false,"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[{"name":"Alimentiv Inc, London, Ontario, N6A 5B6, Canada"},{"name":"Departments of Medicine & Community Health Sciences, Division of Gastroenterology\u00a0& Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, T2N 4Z6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8603-898X","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Alimentiv Inc, London, Ontario, N6A 5B6, Canada"},{"name":"Schulich School of Medicine & Dentistry, Western University, London, Ontario, N6A 5C1, Canada"},{"name":"Department of Epidemiology & Biostatistics, Western University, London, Ontario, N6G 2M1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.035"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.06.043"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.05.048"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-021-00507-5"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00666-8"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033617"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.09.078"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.01.047"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.03.049"},{"issue":"1","key":"e_1_3_3_23_1","doi-asserted-by":"crossref","first-page":"i028","DOI":"10.1093\/ecco-jcc\/jjab232.025","article-title":"OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study","volume":"16","author":"D\u2019Haens G","year":"2022","unstructured":"D\u2019Haens G , KobayashiT , MorrisNet.al OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study. J. Crohn Colitis16(Suppl. 1), i028\u2013i029 (2022).","journal-title":"J. Crohn Colitis"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.08.043"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(22)64060-5"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0084-8"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.12.003"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3707"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.5.2760"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1736"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.05.017"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11535"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315671"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33331-8"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318448"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00377-0"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326390"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab097"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15680"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.10.003"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2022.2095668"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.10.050"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21743"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17628"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.738"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1506764"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101587"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab143"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16609"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.016"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.09.001"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.037"},{"key":"e_1_3_3_59_1","unstructured":"US Food and Drug Administration\n. Ulcerative colitis: developing drugs for treatment. guidance for industry \u2013draft guidance (2022). www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/ulcerative-colitis-developing-drugs-treatment"},{"key":"e_1_3_3_60_1","unstructured":"US Food and Drug Administration\n. Ulcerative colitis: clinical trial endpoints. guidance for industry (2016). www.fda.gov\/files\/drugs\/published\/Ulcerative-Colitis--Clinical-Trial-Endpoints-Guidance-for-Industry.pdf"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.001"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17379"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00492-8"},{"issue":"1","key":"e_1_3_3_65_1","doi-asserted-by":"crossref","first-page":"i042","DOI":"10.1093\/ecco-jcc\/jjab232.035","article-title":"OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study","volume":"16","author":"Sands BE","year":"2022","unstructured":"Sands BE , FeaganBG , SandbornWJet.al OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study. J. Crohn Colitis16(Suppl. 1), i042\u2013i043 (2022).","journal-title":"J. Crohn Colitis"},{"issue":"9","key":"e_1_3_3_66_1","first-page":"406","article-title":"Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature","volume":"17","author":"Gold SL","year":"2021","unstructured":"Gold SL , SteinlaufAF. Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature. Gastroenterol. Hepatol.17(9), 406\u2013414 (2021).","journal-title":"Gastroenterol. Hepatol."},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12170"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.12.003"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2023-0012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T11:05:53Z","timestamp":1715943953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2023-0012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":66,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.2217\/imt-2023-0012"],"URL":"https:\/\/doi.org\/10.2217\/imt-2023-0012","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}